The group that changed the most was the AML, NOS (not otherwise specified) subgroup (n = 212); in detail, 8 patients were divided into the AML with KMT2A-rearrangement subgroup, 25 patients were divided into the AML-MR subgroup, and one case was divided into the AML with NUP98-rearrangement subgroup based on the 5th WHO classification (Figure 1A, Table 2). This evidence concerns the gene KMT2A and acute myeloid leukemia.